近期服用直接口服抗凝药患者的静脉溶栓:目标试验分析及与逆转剂使用的比较
本研究采用目标试验方法分析28个综合卒中中心数据,纳入1342例近期服用DOAC且符合溶栓标准的患者。结果显示IVT组症状性颅内出血发生率3.0%低于未溶栓组5.9%(调整差-2.1%),且功能预后更好(调整差+14.4%)。与新西兰注册中全部使用idarucizumab逆转的患者比较,逆转与未逆转者在安全性和有效性结局上无显著差异。
要点
- 近期服用DOAC患者接受IVT的症状性颅内出血率3.0%,未溶栓组5.9%,调整差-2.1%(95%CI -5.3%至+1.2%)
- IVT组获得良好功能预后(mRS 0-2或恢复基线)的比例更高,调整差+14.4%(95%CI +7.1%至+21.8%)
- IVT前使用逆转剂与未使用逆转剂相比,症状性颅内出血、大出血及有效性结局无显著差异
核心结论
- 目标试验分析证实近期服用DOAC患者接受超说明书IVT的安全性,与既往观察性数据一致。
- 对于确认高DOAC血浆浓度的患者以及IVT前DOAC逆转的有效性和安全性,仍需更多数据和专门试验。
研究设计与样本
- 采用目标试验方法学,分析28个综合卒中中心的数据。
- 纳入服用DOAC、符合IVT标准、NIHSS评分≥2且末次DOAC摄入在48小时内或无法确定的患者,共1342例。
- 中位年龄80岁(IQR 73-86),中位NIHSS评分11,女性占50%,52%接受血管内治疗。
- 342例(25%)接受IVT,其中141例(41.2%)确认入院前<12小时摄入DOAC,92例(26.9%)在12-24小时内。
- 另与新西兰卒中注册中全部接受idarucizumab逆转的患者进行比较。
主要发现
- 症状性颅内出血在接受IVT的328例中发生10例(3.0%),未接受IVT的921例中发生54例(5.9%),调整差-2.1%(95%CI -5.3%至+1.2%)。
- 接受IVT的患者更可能获得良好功能结局,调整差+14.4%(95%CI +7.1%至+21.8%)。
- 比较289例接受逆转(来自新西兰注册)与283例未接受逆转(来自目标试验人群)的IVT患者,症状性颅内出血、大出血或有效性结局均无显著差异。
关键数值与推荐
- 纳入标准:服用DOAC、符合IVT标准、NIHSS评分≥2、末次DOAC摄入在48小时内或无法确定。
- 主要安全性结局:症状性颅内出血、任何颅内出血、大出血、90天死亡率。
- 有效性结局:良好功能结局(改良Rankin量表评分0-2或恢复基线)。
- 调整协变量包括年龄、卒中严重程度、拟行取栓、血糖、血压、DOAC逆转及末次摄入时间。
临床怎么用
- 近期服用DOAC且符合溶栓标准的患者,接受IVT的症状性颅内出血率未显著高于未溶栓者,且功能预后更优。
- IVT前是否使用DOAC逆转剂对安全性和有效性结局无显著影响,支持在不强制逆转的情况下进行IVT。
- 对于确认高DOAC血浆浓度的患者,IVT决策仍需谨慎,等待专门试验数据。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intravenous thrombolysis (IVT) in patients with recent ingestion of direct oral anticoagulants (DOACs) is a frequent challenge and remains controversial. The benefit of DOAC reversal before IVT is uncertain. METHODS: Using target trial methodology, we analyzed data from 28 comprehensive stroke centers. Patients on DOACs were included if they met IVT criteria, had a National Institutes of Health Stroke Scale score of ≥2, and last DOAC intake within 48 hours or was undeterminable. Safety and efficacy outcomes (symptomatic intracerebral hemorrhage, any intracerebral hemorrhage, major bleeding, 90-day mortality, and good functional outcome [modified Rankin Scale score of 0-2 or return to baseline]) were compared between those receiving IVT versus no IVT and IVT with versus without reversal. In addition, a comparison was made with patients from the New Zealand stroke registry, all of whom underwent reversal with idarucizumab. We adjusted for covariates known to be associated with safety and efficacy outcomes, including age, stroke severity, intended thrombectomy, blood glucose, blood pressure, DOAC reversal, and time from last intake. RESULTS: Overall, 1342 patients fulfilled the target trial criteria. The median age was 80 (interquartile range, 73-86) years, median National Institutes of Health Stroke Scale score was 11, 50% were female, and 52% of patients received endovascular therapy. IVT was given in 342 of 1342 (25%) patients. Of these, 141 (41.2%) had verified DOAC intake <12 hours before admission, and 92 (26.9%) within 12 to 24 hours. Symptomatic intracerebral hemorrhage occurred in 10 of 328 (3.0%) of patients receiving IVT and 54 of 921 (5.9%) patients not receiving IVT (adjusted difference, -2.1% [95% CI, -5.3% to +1.2]). Patients receiving IVT were more likely to have good functional outcomes (adjusted difference, +14.4% [95% CI, +7.1% to +21.8%]). Comparing 289 patients with reversal (from the additional New Zealand registry) and 283 patients without reversal before IVT (from the target trial population), there was no significant difference in symptomatic intracerebral hemorrhage, major bleeding, or efficacy outcomes. CONCLUSIONS: This target trial confirms previous observational data regarding the safety of off-label IVT in patients with recent DOAC intake. More data and dedicated trials are needed for patients with confirmed high DOAC plasma levels and regarding the efficacy and safety of DOAC reversal before IVT.
引用
- Meinel TR, Bücke P, D'Anna L, et al. Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use. Stroke. 2025. PMID: 40693390. doi:10.1161/STROKEAHA.125.051384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。